Fig 1.

Susceptibility pattern of initial VIM-CROs isolates from each patient. The susceptibility to the antibiotics listed is shown for the first VIM-CRO isolated from each patient. If a patient had multiple species of VIM-producing CROs isolated, then the first VIM-CRO isolates for each species is shown. Blue indicates susceptibility, yellow indicates intermediate susceptibility, and red indicates resistance to a given antibiotic. The gray boxes represent antibiotic susceptibility data that were unavailable. Amikacin susceptibility was determined prior to the 2023 CLSI update to amikacin breakpoints.